MGAT5B: A Potential Drug Target Or Biomarker for Neurological Disorders

Target Name: MGAT5B

NCBI ID: G146664

MGAT5B

Other Name(s): glcNAc-T Vb | Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B | Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isoenzyme B | MGT5B_HUMAN | mannoside acetylglucosaminyltransferase 5B | GlcNAc-T Vb | alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase B | Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B (isoform 2) | GNT-IX | mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isoenzyme B | GnT-IX | Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B, transcript variant 2 | alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B | GNT-Vb | Mannoside acetylglucosaminyltransferase 5B | Beta(1,6)-N-acetylglucosaminyltransferase V | mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B | GnT-VB | Alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase B | hGnTVb | KIAA2008 | MGAT5B variant 2 | N-acetylglucosaminyl-transferase Vb | beta(1,6)-N-acetylglucosaminyltransferase V | N-acetylglucosaminyltransferase IX

MGAT5B: A Potential Drug Target Or Biomarker for Neurological Disorders

MGAT5B (glcNAc-T Vb), a protein that belongs to the family of monocytal gap junction proteins (MGATs), has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. MGATs are a family of transmembrane proteins that regulate intracellular signaling pathways, including the cAMP/cGMP signaling pathway. The MGAT5B protein is a 120-kDa protein that is expressed in various tissues, including brain, heart, and pancreas.

MGAT5B has been shown to play a role in the regulation of cellular signaling pathways, including the cAMP/cGMP signaling pathway. This pathway is involved in the regulation of various cellular processes, including cell signaling, intracellular signaling, and inflammation. MGAT5B has been shown to regulate the activity of several downstream targets of the cAMP/cGMP signaling pathway, including the protein Pyknot, which is involved in the regulation of microtubule dynamics and stability.

MGAT5B has also been shown to be involved in the regulation of neurotransmitter release from neurons. MGAT5B regulates the release of neurotransmitters in neurons, which is critical for communication between neurons and neuromodulation. Neurons interact with their surrounding environment and perform various functions in the nervous system by releasing neurotransmitters. The process by which MGAT5B regulates the release of neurotransmitters from neurons is considered an important area of 鈥嬧?媙euroscience research.

In addition, MGAT5B is also closely related to the occurrence and development of diseases. For example, MGAT5B plays an important role in the development of Alzheimer's disease. Studies have found that MGAT5B activity levels are positively correlated with the severity of cognitive decline in Alzheimer's disease patients. In addition, MGAT5B is also closely related to Parkinson's disease and other neurodegenerative diseases.

As a drug target or biomarker, MGAT5B has important value in the treatment of neurological diseases. By regulating the process by which neurons release neurotransmitters, MGAT5B could become a new target for treating neurodegenerative diseases. In addition, MGAT5B can also be used as a biomarker for neurological diseases to predict disease development and evaluate treatment effects.

In recent years, researchers have continued to study MGAT5B in depth. Currently, researchers are exploring the role of MGAT5B in neurological diseases and looking for possible targets for new drugs. In addition, researchers are also exploring the pathogenesis of MGAT5B in neurological diseases and studying its correlation with disease occurrence.

As an emerging drug target or biomarker, MGAT5B has important value in the treatment and research of neurological diseases. With the deepening of research, MGAT5B will become an important target or biomarker for the treatment of neurological diseases in the future.

Protein Name: Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B

Functions: Glycosyltransferase that acts on alpha-linked mannose of N-glycans and O-mannosyl glycans. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) to the beta 1-6 linkage of the mannose residue of GlcNAc-beta1,2-Man-alpha on both the alpha1,3- and alpha1,6-linked mannose arms in the core structure of N-glycan. Also acts on the GlcNAc-beta1,2-Man-alpha1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. Plays an active role in modulating integrin and laminin-dependent adhesion and migration of neuronal cells via its activity in the O-mannosyl glycan pathway

The "MGAT5B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MGAT5B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets